公开(公告)号：US20240327485A1

公开(公告)日：2024-10-03

申请号：US18627094

申请日：2024-04-04

Applicant: Amgen Inc.

Inventor： Marc Alain GAVIN ,  Gunasekaran KANNAN ,  Li Li ,  Joshua Thomas PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  A61K38/00 ,  C07K16/00

CPC classification number: C07K14/55 ,  C07K16/00 ,  A61K38/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US20210094997A1

公开(公告)日：2021-04-01

申请号：US17063566

申请日：2020-10-05

Applicant: Amgen Inc.

Inventor： Marc Alain GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua Thomas PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/00

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.